2 Cheap Healthcare Stocks to Consider Buying Right Now

NYSE: CI | Cigna Corporation  News, Ratings, and Charts

CI – The COVID-19 pandemic has accelerated the growth of the healthcare industry. Moreover, investors are becoming increasingly bullish on the prospects of the industry due to the healthcare needs of the U.S.’ aging population and growing investments in care for that demographic. So, we think it could be wise to bet now on cheap healthcare stocks Cigna (CI) and Cardinal (CAH).

The healthcare industry has witnessed substantial capital inflows over the past year as the federal government spent liberally to fight the COVID-19 pandemic. This funding has allowed several companies to upgrade their operations with new machinery and equipment purchases and additional personnel.  

As the country recovers from the public health crisis, elective surgeries and the healthcare needs of the growing U.S. elderly population should keep driving the industry’s growth.

Investors’ interest in healthcare stocks is evidenced by the Health Care Select Sector SPDR Fund’s (XLV) 5.4% gains over the past month. But the increasing investor focus has made many healthcare stocks expensive now. As such, we think affordable healthcare stocks Cigna Corporation (CI) and Cardinal health, Inc. (CAH) could be solid additions to one’s portfolio.

Click here to checkout our Healthcare Sector Report for 2021

Cigna Corporation (CI)

CI is a health services company that offers medical and dental insurance and related products and services. The company operates through three segments—Evernorth, U.S. Medical and International Markets.

CI’s revenue increased 9.1% year-over-year to $41.71 billion in the fourth quarter, ended December 31, 2020. The company’s net income came in $4.13 billion, which represents a 323.2% increase from the same period last year. Its EPS was  $11.45, up 340.4% from the year-ago value.

Analysts expect CI’s EPS to increase 9.8% year-over-year to $20.26 for its fiscal year 2021. It surpassed consensus EPS estimates in three of the trailing four quarters. Its revenue is expected to come in at $41.13 billion during the quarter ending June 30,  which represents an 8.9% year-over-year rise.

On April 9, CI and Oscar Health Inc. (OSCR) jointly launched a new health insurance product named Cigna + Oscar, which is designed for small businesses. The product should help small businesses provide their employees with access to affordable, member-first, health insurance products. The stock has gained 40.6% over the past year to close yesterday’s trading session at $259.50.

CI’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall A rating, which equates to Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

The stock has an A grade for Value, and a B grade for Sentiment, Growth and Quality. Click here to access CI’s ratings for Momentum and Stability as well.

CI is ranked #1 of 11 stocks in the B-rated Medical- Health insurance industry.

Cardinal health, Inc. (CAH)

CAH is a healthcare services and products company. The company operates through two segments: Pharmaceutical and Medical.

For its fiscal year 2021 second quarter, the company’s revenue increased 5% year-over-year to $41.5 billion. Its  operating earnings were  $461 million, indicating a 38% rise year-over-year. Its net earnings increased 185.9% from the prior-year quarter to $629 million. And its EPS stood at $2.13, representing an 184% rise from the same period last year.

Analysts expect CAH’s EPS to be  $1.21 for the quarter ending June 30, which represents an 16.3% increase from its  year-ago value. It surpassed the Street’s EPS estimates in each of the trailing four quarters. The company’s revenue is expected to increase 10% year-over-year to $40.40 billion for the current quarter.

On April 9, CAH introduced Cardinal Health Navista Tech Solutions (TS), an advanced suite of technology solutions. This latest launch should enable community oncologists to boost patient outcomes and lower costs with respect to their treatment while they shift to value-based care. The introduction is likely to bolster the performance of CAH’s Pharmaceutical segment. The stock has gained 31.9% over the past year and closed yesterday’s trading session at $62.02.

CAH’s POWR Ratings reflect this promising outlook. The stock has an overall A grade, which signals Strong Buy. It has an A grade for Value, and a B grade for Growth, Sentiment and Stability. Click here to see the additional POWR Ratings for CAH (Quality and Momentum).

CAH is ranked #4 of 78 stocks in the Medical – Services industry.

Click here to checkout our Healthcare Sector Report for 2021


CI shares were unchanged in after-hours trading Wednesday. Year-to-date, CI has gained 24.66%, versus a 11.56% rise in the benchmark S&P 500 index during the same period.


About the Author: Ananyo Guha Niyogi


Ananyo’s ardent interest in capital markets, wealth management, and financial regulatory issues, led him to a career as an investment analyst. His goal is to educate individual investors by making complex financial issues easy to understand. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CIGet RatingGet RatingGet Rating
CAHGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

The Fallacy of “Peak Everything”

Connected to the inflation conversation is the theory of “Peak Everything”. This idea is making its rounds through the investing world with shock waves of trading activity. Let’s talk about what it is...What it really means for the future of the S&P 500 (SPY)...And why, we will end up on the right side of action. Read on below to find out more…

:  |  News, Ratings, and Charts

Could the Fed’s Rate Reversal Lead to More Volatility in the Stock Market?

Inflation has become a recurring theme in my comments due to a notable rise in inflation metrics and how they have affected the S&P 500 (SPY). The Fed has consistently spoken of inflation being transitory over the past couple of months, which has resulted in investors becoming less concerned over higher prices. But it appeared that the Fed reversed course as it is now, indicating it would raise rates ahead of schedule. This created more volatility in the markets leading to a tough day on Friday. But, if you look closer at their remarks, not everything is as it seems. I will expand on my point below. But first, let's recap the past week in the markets. Read on below…

:  |  News, Ratings, and Charts

2nd Half of 2021 Stock Market Outlook

The stock market (SPY) has continued on a bullish path to start 2021. Yet it is not quite the same glorious bull run we enjoyed from the lows of last year. This market has become more volatile and with less upside potential. However, there is still plenty of money to be made if you look in the right places. That is the very nature of the new presentation I put together. So read on for more info…

:  |  News, Ratings, and Charts

3 Top Biotech Stocks To Bolster Your Portfolio

Illumina (ILMN), Jazz Pharmaceuticals (JAZZ), and Amgen (AMGN) are 3 of the top biotech stocks. The sector has been an underperformer over the last few years but could start outperforming given the aging population, low valuation, and growth potential.

:  |  News, Ratings, and Charts

2nd Half of 2021 Stock Market Outlook

The stock market (SPY) has continued on a bullish path to start 2021. Yet it is not quite the same glorious bull run we enjoyed from the lows of last year. This market has become more volatile and with less upside potential. However, there is still plenty of money to be made if you look in the right places. That is the very nature of the new presentation I put together. So read on for more info…

Read More Stories

More Cigna Corporation (CI) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CI News